Literature DB >> 32593612

Critical residue properties for potency and selectivity of α-Conotoxin RgIA towards α9α10 nicotinic acetylcholine receptors.

Peter N Huynh1, Peta J Harvey2, Joanna Gajewiak3, David J Craik2, J Michael McIntosh4.   

Abstract

The α9α10 nicotinic acetylcholine receptor (nAChR) has been characterized as an effective anti-pain target that functions through a non-opioid mechanism. However, as a pentameric ion channel comprised of two different subunits, the specific targeting of α9α10 nAChRs has proven challenging. Previously the 13-amino-acid peptide, RgIA, was shown to block α9α10 nAChRs with high potency and specificity. This peptide, characterized from the venom of the carnivorous marine snail, Conus regius, produced analgesia in several rodent models of chronic pain. Despite promising pre-clinical data in behavioral assays, the number of specific α9α10 nAChR antagonists remains small and the physiological mechanisms of analgesia remain cryptic. In this study, we implement amino-acid substitutions to definitively characterize the chemical properties of RgIA that contribute to its activity against α9α10 nAChRs. Using this mutational approach, we determined the vital role of biochemical side-chain properties and amino acids in the second loop that are amenable to substitutions to further engineer next-generation analogs for the blockade of α9α10 nAChRs.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Analgesia; Conotoxin; Nicotinic; Structure-activity relationship; nAChR

Mesh:

Substances:

Year:  2020        PMID: 32593612      PMCID: PMC7572646          DOI: 10.1016/j.bcp.2020.114124

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  36 in total

1.  Molecular basis for the differential sensitivity of rat and human α9α10 nAChRs to α-conotoxin RgIA.

Authors:  Layla Azam; J Michael McIntosh
Journal:  J Neurochem       Date:  2012-08-03       Impact factor: 5.372

Review 2.  The vagus nerve and the nicotinic anti-inflammatory pathway.

Authors:  Luis Ulloa
Journal:  Nat Rev Drug Discov       Date:  2005-08       Impact factor: 84.694

3.  Alpha-RgIA: a novel conotoxin that specifically and potently blocks the alpha9alpha10 nAChR.

Authors:  Michael Ellison; Christian Haberlandt; María Eugenia Gomez-Casati; Maren Watkins; A Belén Elgoyhen; J Michael McIntosh; Baldomero M Olivera
Journal:  Biochemistry       Date:  2006-02-07       Impact factor: 3.162

4.  Molecular evolution of the nicotinic acetylcholine receptor: an example of multigene family in excitable cells.

Authors:  N Le Novère; J P Changeux
Journal:  J Mol Evol       Date:  1995-02       Impact factor: 2.395

5.  Evolution of nicotinic acetylcholine receptor subunits.

Authors:  K Tsunoyama; T Gojobori
Journal:  Mol Biol Evol       Date:  1998-05       Impact factor: 16.240

6.  Inhibition of α9α10 nicotinic acetylcholine receptors prevents chemotherapy-induced neuropathic pain.

Authors:  Haylie K Romero; Sean B Christensen; Lorenzo Di Cesare Mannelli; Joanna Gajewiak; Renuka Ramachandra; Keith S Elmslie; Douglas E Vetter; Carla Ghelardini; Shawn P Iadonato; Jose L Mercado; Baldomera M Olivera; J Michael McIntosh
Journal:  Proc Natl Acad Sci U S A       Date:  2017-02-21       Impact factor: 11.205

7.  Characterization of the human nicotinic acetylcholine receptor subunit alpha (alpha) 9 (CHRNA9) and alpha (alpha) 10 (CHRNA10) in lymphocytes.

Authors:  Huashan Peng; Robert L Ferris; Tonya Matthews; Hakim Hiel; Andres Lopez-Albaitero; Lawrence R Lustig
Journal:  Life Sci       Date:  2004-12-03       Impact factor: 5.037

8.  α-conotoxin RgIA protects against the development of nerve injury-induced chronic pain and prevents both neuronal and glial derangement.

Authors:  Lorenzo Di Cesare Mannelli; Lorenzo Cinci; Laura Micheli; Matteo Zanardelli; Alessandra Pacini; J Michael McIntosh; Carla Ghelardini
Journal:  Pain       Date:  2014-07-05       Impact factor: 6.961

9.  Oligoarginine Peptides, a New Family of Nicotinic Acetylcholine Receptor Inhibitors.

Authors:  Dmitry S Lebedev; Elena V Kryukova; Igor A Ivanov; Natalia S Egorova; Nikita D Timofeev; Ekaterina N Spirova; Elizaveta Yu Tufanova; Andrei E Siniavin; Denis S Kudryavtsev; Igor E Kasheverov; Marios Zouridakis; Ramaz Katsarava; Nino Zavradashvili; Ia Iagorshvili; Socrates J Tzartos; Victor I Tsetlin
Journal:  Mol Pharmacol       Date:  2019-09-06       Impact factor: 4.436

10.  RgIA4 Potently Blocks Mouse α9α10 nAChRs and Provides Long Lasting Protection against Oxaliplatin-Induced Cold Allodynia.

Authors:  Sean B Christensen; Arik J Hone; Isabelle Roux; Julie Kniazeff; Jean-Philippe Pin; Grégory Upert; Denis Servent; Elisabeth Glowatzki; J Michael McIntosh
Journal:  Front Cell Neurosci       Date:  2017-07-21       Impact factor: 5.505

View more
  3 in total

Review 1.  Marine Origin Ligands of Nicotinic Receptors: Low Molecular Compounds, Peptides and Proteins for Fundamental Research and Practical Applications.

Authors:  Igor Kasheverov; Denis Kudryavtsev; Irina Shelukhina; Georgy Nikolaev; Yuri Utkin; Victor Tsetlin
Journal:  Biomolecules       Date:  2022-01-23

2.  Discovery of Methylene Thioacetal-Incorporated α-RgIA Analogues as Potent and Stable Antagonists of the Human α9α10 Nicotinic Acetylcholine Receptor for the Treatment of Neuropathic Pain.

Authors:  Nan Zheng; Sean B Christensen; Cheryl Dowell; Landa Purushottam; Jack J Skalicky; J Michael McIntosh; Danny Hung-Chieh Chou
Journal:  J Med Chem       Date:  2021-06-23       Impact factor: 7.446

3.  Selective Penicillamine Substitution Enables Development of a Potent Analgesic Peptide that Acts through a Non-Opioid-Based Mechanism.

Authors:  Joanna Gajewiak; Sean B Christensen; Cheryl Dowell; Fuaad Hararah; Fernando Fisher; Peter N Huynh; Baldomero M Olivera; J Michael McIntosh
Journal:  J Med Chem       Date:  2021-06-18       Impact factor: 8.039

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.